ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 83 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,173,153 | -31.1% | 463,234 | +4.3% | 0.00% | 0.0% |
| Q2 2023 | $4,606,987 | +38.8% | 444,261 | +8.3% | 0.00% | 0.0% |
| Q1 2023 | $3,318,680 | -48.9% | 410,220 | -0.5% | 0.00% | -50.0% |
| Q4 2022 | $6,491,095 | +2.4% | 412,133 | +2.4% | 0.00% | 0.0% |
| Q3 2022 | $6,337,000 | +194.1% | 402,554 | +160.9% | 0.00% | +100.0% |
| Q2 2022 | $2,155,000 | -6.1% | 154,319 | +16.0% | 0.00% | 0.0% |
| Q1 2022 | $2,295,000 | +22.4% | 133,068 | +3.2% | 0.00% | 0.0% |
| Q4 2021 | $1,875,000 | -17.9% | 128,913 | +1.6% | 0.00% | 0.0% |
| Q3 2021 | $2,285,000 | +20.6% | 126,916 | +17.7% | 0.00% | 0.0% |
| Q2 2021 | $1,894,000 | +375.9% | 107,838 | +583.0% | 0.00% | – |
| Q1 2021 | $398,000 | +199.2% | 15,789 | -23.0% | 0.00% | – |
| Q4 2020 | $133,000 | +150.9% | 20,505 | 0.0% | 0.00% | – |
| Q3 2020 | $53,000 | +55.9% | 20,505 | 0.0% | 0.00% | – |
| Q2 2020 | $34,000 | -61.8% | 20,505 | -75.8% | 0.00% | – |
| Q1 2020 | $89,000 | -44.7% | 84,702 | 0.0% | 0.00% | – |
| Q4 2019 | $161,000 | +75.0% | 84,702 | 0.0% | 0.00% | – |
| Q3 2019 | $92,000 | -79.7% | 84,702 | -59.0% | 0.00% | – |
| Q2 2019 | $453,000 | -56.5% | 206,589 | +18.8% | 0.00% | -100.0% |
| Q1 2019 | $1,042,000 | -29.5% | 173,830 | -13.1% | 0.00% | 0.0% |
| Q4 2018 | $1,478,000 | -24.1% | 199,933 | +49.1% | 0.00% | 0.0% |
| Q3 2018 | $1,947,000 | -20.2% | 134,059 | +9.8% | 0.00% | -50.0% |
| Q2 2018 | $2,440,000 | +10.9% | 122,143 | -2.7% | 0.00% | 0.0% |
| Q1 2018 | $2,200,000 | -26.7% | 125,569 | +3.1% | 0.00% | 0.0% |
| Q4 2017 | $3,003,000 | +25.8% | 121,767 | +31.6% | 0.00% | 0.0% |
| Q3 2017 | $2,388,000 | +42.5% | 92,507 | +49.8% | 0.00% | 0.0% |
| Q2 2017 | $1,676,000 | +27.8% | 61,765 | +40.5% | 0.00% | +100.0% |
| Q1 2017 | $1,311,000 | +17.2% | 43,961 | +6.6% | 0.00% | 0.0% |
| Q4 2016 | $1,119,000 | +77.9% | 41,225 | +68.1% | 0.00% | 0.0% |
| Q3 2016 | $629,000 | +43.3% | 24,531 | +3.4% | 0.00% | 0.0% |
| Q2 2016 | $439,000 | +37.2% | 23,715 | +40.6% | 0.00% | – |
| Q1 2016 | $320,000 | -28.4% | 16,863 | +1.8% | 0.00% | -100.0% |
| Q4 2015 | $447,000 | – | 16,557 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |